Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
85
Years old
Gender
Female
Therapeutic area :
Oncology
Disease :
Breast cancer
Study medication :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Start Date :
April 10, 2010
End date :
June 17, 2015
Study ID :
PM0259 CA 228 BO
EudraCT/CTIS number :
2009-014497-18
Send by email